Latest Etoricoxib Stories
An updated study published in this week's PLoS Medicine gives some new information on the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) and suggests that among these commonly used drugs, naproxen and low dose ibuprofen are least likely to increase cardiovascular risk whereas diclofenac, even in doses available without prescription, elevates risk.
An updated study gives new information on the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) and suggests that naproxen, a commonly used drug, and low dose ibuprofen are least likely to increase cardiovascular risks.
A new study published in the British Medical Journal (BMJ) on Wednesday warns that taking specific types of pain relievers could increase a person's risk of suffering a stroke or other heart-related ailment.
U.S. firm Merck said Monday its new COX 2 painkiller -- in the same class as Vioxx -- has a cardiac risk similar to Novartis' Voltaren.
Merck & Co. on Wednesday said the experimental arthritis drug Arcoxia, in a study, met its main goal of causing no more blood clot-related heart attacks than a standard treatment, but more patients taking Arcoxia withdrew from the trial due to serious side effects.
Drugmaker Merck & Co. on Wednesday gave preliminary results of a study of its investigational painkiller Arcoxia, the planned successor to Vioxx, which was pulled off the market in 2004 after being linked to stroke and heart attack.
WHITEHOUSE STATION, NJ: The Vioxx recall has not appeared to have hurt competitor drugs that stop pain in a similar fashion, and that could spell good news for Merck's next pain product, Arcoxia.
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.